<scp>Anti‐PD1</scp> or <scp>anti‐PD‐L1</scp> antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer-Reference-Cited by-同舟云学术

Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer

Published:2022-02-24 Issue:7 Volume:13 Page:1104-1105
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Zhang Xuexia¹,Cai Xiaoping²,Zheng Hao²^ORCID

Affiliation:

1. Department Internal Medicine Sixth affiliated Hospital of Wenzhou Medical University, Lishui People's Hospital Lishui PR China

2. Department of Respiratory and Intensive Care Unit Sixth affiliated Hospital of Wenzhou Medical University, Lishui People's Hospital Lishui PR China

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14358

Reference5 articles.

1. Management of Patients with Advanced Non-Small Cell Lung Cancer

2. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management

3. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

4. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

5. Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive analysis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs): A SEER database analysis of 767 cases;Frontiers in Oncology;2023-01-09